Condition
Myelodysplastic Syndrome (MDS)/AML
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Not Yet Recruiting1
Recruiting1
Terminated1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07532824Phase 1Recruiting
Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS
NCT06563804Phase 1Terminated
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
NCT07347418Phase 1Not Yet Recruiting
CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML or HR-MDS
Showing all 3 trials